title: Humanization and simultaneous optimization of monoclonal antibody.
abstract: Antibody humanization is an essential technology for reducing the potential risk of immunogenicity associated with animal-derived antibodies and has been applied to a majority of the therapeutic antibodies on the market. For developing an antibody molecule as a pharmaceutical at the current biotechnology level, however, other properties also have to be considered in parallel with humanization in antibody generation and optimization. This section describes the critical properties of therapeutic antibodies that should be sufficiently qualified, including immunogenicity, binding affinity, physiochemical stability, expression in host cells and pharmacokinetics, and the basic methodologies of antibody engineering involved. By simultaneously optimizing the antibody molecule in the light of these properties, it should prove possible to shorten the research and development period necessary to identify a highly qualified clinical candidate and consequently accelerate the start of the clinical trial.
authors.affiliation: Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kuramochi
authors.forename: T
authors.initials: T
authors.lastname: Igawa
authors.forename: H
authors.initials: H
authors.lastname: Tsunoda
authors.forename: K
authors.initials: K
authors.lastname: Hattori
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000302:isolation & purification / Q000494:pharmacology / Q000502:physiology*; D000915:Antibody Affinity / Q000276:immunology; D000918:Antibody Specificity / Q000276:immunology; D006801:Humans; D015202:Protein Engineering / Q000379:methods
chemical_list: D061067:Antibodies, Monoclonal, Humanized